Ισραήλ - Αγγλικά - Ministry of Health

rafa laboratories ltd - lidocaine hydrochloride - gel - lidocaine hydrochloride 2 % - local anesthetic, not to be used for procedures requiring sterile products

Ισραήλ - Αγγλικά - Ministry of Health

rafa laboratories ltd - oxycodone hydrochloride - syrup - oxycodone hydrochloride 10 mg / 5 ml - oxycodone - oxycodone - for use in the relief of moderate to severe pain.

Ισραήλ - Αγγλικά - Ministry of Health

rafa laboratories ltd - midazolam - solution for injection - midazolam 1 mg/ml - midazolam - midazolam - midazolam is a short-acting sleep-inducing drug that is indicated:in adults• conscious sedation before and during diagnostic or therapeutic procedures with or without local anaesthesia• anaesthesia- premedication before induction of anaesthesia- induction of anaesthesia- as a sedative component in combined anaesthesia• sedation in intensive care unitsin children• conscious sedation before and during diagnostic or therapeutic procedures with or without local anaesthesia• anaesthesia- premedication before induction of anaesthesia• sedation in intensive care units

Ισραήλ - Αγγλικά - Ministry of Health

rafa laboratories ltd - midazolam - solution for injection - midazolam 5 mg/ml - midazolam - midazolam - midazolam is a short-acting sleep-inducing drug that is indicated:in adults• conscious sedation before and during diagnostic or therapeutic procedures with or without local anaesthesia• anaesthesia- premedication before induction of anaesthesia- induction of anaesthesia- as a sedative component in combined anaesthesia• sedation in intensive care unitsin children• conscious sedation before and during diagnostic or therapeutic procedures with or without local anaesthesia• anaesthesia- premedication before induction of anaesthesia• sedation in intensive care units

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - gliclazide - oral tablet - 80mg

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - tramadol hydrochloride - oral capsule - 50mg

Ισραήλ - Αγγλικά - Ministry of Health

rafa laboratories ltd - lidocaine hydrochloride - solution for injection - lidocaine hydrochloride 20 mg/ml - lidocaine - lidocaine - local and regional anaesthesia.severe symptomatic ventricular tachycardia or tachy-arrhythmia, if assessed to be life-threatening.

Ισραήλ - Αγγλικά - Ministry of Health

rafa laboratories ltd - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - tablets prolonged release - oxycodone hydrochloride 10 mg; naloxone hydrochloride (as dihydrate) 5 mg - naloxone - naloxone - targin is indicated for the relief of moderate to severe pain.the oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. the opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.

Ισραήλ - Αγγλικά - Ministry of Health

rafa laboratories ltd - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - tablets prolonged release - oxycodone hydrochloride 20 mg; naloxone hydrochloride (as dihydrate) 10 mg - naloxone - naloxone - targin is indicated for the relief of moderate to severe pain.the oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. the opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut

Ισραήλ - Αγγλικά - Ministry of Health

rafa laboratories ltd - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - tablets prolonged release - oxycodone hydrochloride 5 mg; naloxone hydrochloride (as dihydrate) 2.5 mg - naloxone - naloxone - targin is indicated for the relief of moderate to severe pain.the oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. the opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.